EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical Translation

Ayesha Siddika iD, Joël Rousseau, Félix Veillette, Camille Bouchard iD, Yaoyao Lu iD, Jacques P Tremblay iD

Cells · 2026

DOI: 10.3390/cells15100852 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Ayesha Siddika und 5 weiteren Autor:innen. Beteiligte Einrichtung: Département de Médecine Moléculaire, Université Laval, Québec, QC G1V 0A6, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Gene Editing, Translational Research, Biomedical, Genetic Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 277 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defeat Duchenne Foundation ; VCGS (CIHR), Defeat Duchenne Foundation, Vanier Canada Graduate Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) remains a major challenge in genetic medicine due to the difficulty of achieving durable, body-wide restoration of dystrophin in post-mitotic muscle tissues. Although current therapies—including exon skipping and micro-dystrophin gene replacement—have demonstrated clinical feasibility, their benefits are limited by incomplete efficacy, mutation specificity, and the need for repeated or high-dose interventions. These limitations highlight the need for strategies capable of directly and permanently correcting the underlying genetic defect. Recent advances in genome editing have positioned CRISPR-based technologies as promising candidates for this objective. Rather than functioning as a single approach, gene-editing platforms encompass a spectrum of strategies—including exon deletion, exon reframing, base editing, and prime editing—each with distinct advantages depending on the mutational context. In particular, the emergence of precision editing tools has enabled controlled nucleotide-level modifications, expanding the range of correctable mutations while reducing reliance on double-strand DNA breaks. In this review, we adopt a comparative and translational perspective to evaluate gene-editing strategies for DMD. We examine how different approaches align with specific mutation types, summarize key findings from preclinical studies, and analyze the major barriers to clinical implementation, including delivery efficiency, immune responses, editing durability, and genomic safety. We further discuss emerging innovations in editing technologies and delivery systems that aim to address these limitations. Collectively, this work reframes gene editing as a decision-oriented and application-driven therapeutic framework. Continued integration of advances in genome engineering, delivery platforms, and muscle biology will be essential to translate these technologies into safe, effective, and durable treatments capable of altering the clinical trajectory of DMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneGene EditingTranslational Research, BiomedicalGenetic TherapyHumansAnimalsDystrophinCRISPR-Cas SystemsMutation

Stichwörter der Autor:innen

CRISPR/Cas9DMD geneDuchenne muscular dystrophy (DMD)base editingdystrophingene editing therapyprime editingtranslational therapy

Substanzen

Dystrophin

Autor:innen und Institutionen

  • Département de Médecine Moléculaire, Université Laval, Québec, QC G1V 0A6, Canada.
  • Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1E 6W2, Canada.

ORCID-Profile: Ayesha Siddika, Camille Bouchard, Yaoyao Lu, Jacques P Tremblay

Förderung

  • Defeat Duchenne Foundation ; VCGS (CIHR)
  • Defeat Duchenne Foundation
  • Vanier Canada Graduate Scholarship

Zitieren

APA

Siddika, A., Rousseau, J., Veillette, F., Bouchard, C., Lu, Y., & Tremblay, J. P. (2026). Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical Translation. Cells. https://doi.org/10.3390/cells15100852

Vancouver

Siddika A, Rousseau J, Veillette F, Bouchard C, Lu Y, Tremblay JP. Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical Translation. Cells. 2026. doi:10.3390/cells15100852

BibTeX
@article{Siddika2026,
  author = {Siddika, Ayesha and Rousseau, Joël and Veillette, Félix and Bouchard, Camille and Lu, Yaoyao and Tremblay, Jacques P},
  title = {Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical Translation},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15100852}
}
Kostenlos starten →